Medford, United States
Hepregen Corporation, founded in 2007, is a biotechnology firm committed to revolutionizing drug metabolism understanding in the liver. Based in the United States, the company leverages its patented HepatoPac platform, a micro-patterned co-culture system, to transform drug development and safety assessment processes. By miniaturizing a human liver model using semiconductor microtechnology, Hepregen provides a predictive platform that's seamlessly integrated into pharmaceutical workflows.
The HepatoPac technology replicates in vivo liver functions, supporting applications from toxicity screening to efficacy assessment and biomarker identification. Importantly, it can be adapted for high-content screening in drug metabolism and pharmacokinetics (DMPK) analysis, enhancing safety and efficacy insights during preclinical phases. With over 20 pharmaceutical partnerships since its inception, Hepregen stands at the forefront of drug discovery innovation.
Initially spun out and backed by Battelle Ventures from MIT, the company received a $500.00K grant investment as of June 2012, evidencing its robust developmental trajectory. With its focus on patient impact, Hepregen Corporation is ideally positioned for investors seeking cutting-edge, integrative solutions within biotechnology and healthcare.
